PAIN THERAPEUTICS, INC. Patent applications |
Patent application number | Title | Published |
20140193490 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS - The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats. | 07-10-2014 |
20140186437 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS - The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats. | 07-03-2014 |
20090203722 | Novel compositions and methods for enhancing potency or reducing adverse side effects of opiold agonists - The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency without attenuating an adverse side effect of the agonist, or alternatively maintain the analgesic potency of the agonist while attenuating an adverse side effect of the agonist. The invention additionally relates to novel opioid compositions and methods for the gender-based dosing of men and women. | 08-13-2009 |
20090165578 | DISSOLUTION TEST EQUIPMENT AND METHODS FOR TESTING - Dissolution test equipment (e.g., apparatus) and methods for testing are disclosed. Such methods and equipment may be advantageously used for testing of drug or active pharmaceutical ingredient (API) preparations, including drug formulations and dosage forms. | 07-02-2009 |
20090164240 | METHODS FOR CONDUCTING A CLINICAL TRIAL - The present disclosure relates generally to methods for selecting subjects for a clinical trial and includes methods for conducting a clinical trial to study the efficacy and/or safety of a drug by selecting subjects, for inclusion in a subsequent double-blind treatment period of the clinical trial, that do not exhibit adverse events to the drug. Methods for conducting a clinical trial may comprise the following: (1) an open-label titration period, (2) an adjustable dose treatment period and (3) a fixed dose treatment period. Optionally, the clinical trial may comprise a washout period prior to the open-label titration period. Also provided are methods for doing business by selecting subjects for a clinical trial for a drug that do not exhibit adverse events to the drug. Such methods may generate, revenue by reducing the length of time required to complete the clinical trial, increasing the likelihood that the drug will obtain regulatory approval and/or reducing the length of time it takes to bring advance the drug to market. | 06-25-2009 |